The MABA approach: A new option to improve bronchodilator therapy

European Respiratory Journal

Volumn 42, Issue 4, 2013, Pages 885-887

  Cazzola, Mario ^a   Lopez Campos, Jose Luis ^b,c   Puente Maestu, Luis ^d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CATECHOLAMINE; CORTICOSTEROID; GSK 961081; IPRATROPIUM BROMIDE; MUSCARINIC BETA2 AGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DOSE COMPARISON; DRUG FORMULATION; FORCED EXPIRATORY VOLUME; HUMAN; MEDICATION COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE;

BRONCHODILATOR AGENTS; CARBAMATES; FEMALE; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES;

EID: 84886523953     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00067013     Document Type: Review

References (22)

1. Rodrigo GJ, Plaza V, Castro-Rodriguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther 2012; 25: 40-47.
2. Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD 2009; 6: 404-415.
3. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012; 21: 101-108.
4. Cazzola M, Molimard M. The scientific rationale for combining long-acting b2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010; 23: 257-267.
5. Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012; 64: 450-504.
6. López-Campos JL. Interaccion M-beta: bases para el tratamiento broncodilatador combinado [M2-b2 interaction: a basis for combined bronchodilator treatment]. Arch Bronconeumol 2013; 49: 279-281.
7. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
8. Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs Today (Barc) 2012; 48: 785-794.
9. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155: 179-191.
10. Ágh T, Inotai A, Mészáros Á. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration 2011; 82: 328-334.
11. Simoni-Wastila L, Wei YJ, Qian J, et al. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population. Am J Geriatr Pharmacother 2012; 10: 201-210.
12. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008; 63: 831-838.
13. Hughes AD, McNamara A, Steinfeld T. Multivalent dual pharmacology muscarinic antagonist and b2 agonist (MABA) molecules for the treatment of COPD. Prog Med Chem 2012; 51: 71-95.
14. Gross NJ. The COPD pipeline. COPD 2010; 7: 154-156.
15. Hughes AD, Jones LH. Dual-pharmacology muscarinic antagonist and b2-agonist molecules for the treatment of chronic obstructive pulmonary disease. Future Med Chem 2011; 3: 1585-1605.
16. Norman P. Novel dihydroquinoline-based MABAs; clues to the identity of LAS-190792: evaluation of WO20111411802. Expert Opin Ther Pat 2012; 22: 185-192.
17. Wielders PLML, Ludwig-Sengpiel A, Locantore N, et al. A new class of bronchodilator improves lung function in COPD: A trial with GSK961081. Eur Respir J 2013; 42: 972-981.
18. Bateman ED, Kornmann O, Ambery C, et al. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther 2013 [in press DOI: 10.1016/j.pupt.2013.03.015].
19. Norris V, Ambery C. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD. Pulm Pharmacol Ther 2013 [in press DOI: 10.1016/j.pupt.2013.03.009].
20. Penn RB, Benovic JL. Regulation of heterotrimeric G protein signaling in airway smooth muscle. Proc Am Thorac Soc 2008; 5: 47-57.
21. Haney S, Hancox RJ. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial. Respir Res 2005; 6: 107.
22. Wilding PJ, Clark MM, Pavord ID, et al. Effect of cessation of short-term therapy with ipratropium bromide on lung function and airway responsiveness. Eur Respir J 1996; 9: 1627-1631.